Figure 3From: A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialRelationship between days to pegfilgrastim concentration falling below 2 ng/mL and days to absolute neutrophil count > 0.5 × 109/LBack to article page